IFG Advisory LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.0% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 10,476 shares of the biopharmaceutical company’s stock after selling 2,454 shares during the quarter. IFG Advisory LLC’s holdings in Gilead Sciences were worth $808,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently modified their holdings of the company. Reilly Financial Advisors LLC grew its holdings in shares of Gilead Sciences by 98.3% in the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 704 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Gilead Sciences in the second quarter worth $132,000. Brand Asset Management Group Inc. bought a new stake in shares of Gilead Sciences in the second quarter worth $139,000. TRUE Private Wealth Advisors bought a new stake in shares of Gilead Sciences in the third quarter worth $174,000. Finally, Truvestments Capital LLC bought a new stake in shares of Gilead Sciences in the third quarter worth $210,000. 78.09% of the stock is owned by institutional investors.
In other news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $78.04, for a total value of $3,902,000.00. Following the transaction, the director now directly owns 3,067,762 shares in the company, valued at $239,408,146.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 150,000 shares of company stock worth $11,087,500 over the last 90 days. Company insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences stock opened at $71.18 on Friday. Gilead Sciences, Inc. has a 52 week low of $64.27 and a 52 week high of $89.54. The stock has a market capitalization of $93.76 billion, a PE ratio of 11.29, a price-to-earnings-growth ratio of -2.81 and a beta of 1.01. The company has a current ratio of 3.45, a quick ratio of 3.39 and a debt-to-equity ratio of 1.09.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The business had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.44 billion. During the same period in the previous year, the business earned $2.27 earnings per share. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 6.44 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be given a $0.57 dividend. The ex-dividend date is Thursday, December 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.20%. Gilead Sciences’s payout ratio is 26.64%.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Article: Hedge Funds – How They Work For Investors
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.